Sysmex is active in a broad spectrum of healthcare areas. In addtion
to information for healthcare professionals we also provide
applied information for privat individuals seeking assistance in our
areas of expertise.
At the moment we provide guidance and background info on
breast cancer. We welcome you to visit http://www.breast-cancer-diagnosis.co.uk/
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and the National Cancer Center (Location: Tokyo, Japan: President: Hitoshi Nakagama) are jointly developing a cancer-related gene panel testing system. On February 28, 2017, this system received the first designation under the Ministry of Health, Labour and Welfare’s Sakigake Designation System1 for in vitro diagnostic pharmaceuticals.
Genomic medicine involves studying individuals’ genetic information included in DNA and diagnosing, treating and preventing disease more efficiently and effectively based on the results obtained. In the realization of genomic medicine, high-quality testing system configuration and quality control of testing have arisen as issues.
Genomic medicine for cancer requires a cancer-related gene panel2, next-generation sequencer3 and an analysis program. The cancer-related gene panel testing system (the “System”) that has been designated under the Sakigake Designation System comprises these three elements. The System enables the simultaneous analysis of more than 100 types of genetic mutation. This System allows for multiple gene mutations to be detected from specimens (cancer tissue) of patients for whom standard treatment (including treatment with anti-cancer drugs) has been concluded or is expected to conclude, supporting decisions on treatment methods once standard treatments have ended.
Sysmex and the National Cancer Center have opened a laboratory that meets international standards with the National Cancer Center Hospital, and have been pursuing clinical research toward the introduction of genomic medicine into routine clinical practice. Sysmex and the National Cancer Center plan to use the System in the cancer diagnostic panel (NCC Oncopanel) that the National Cancer Center has developed for this research.
Sysmex will work toward the earliest possible development of new cancer diagnostic methods, with the aim of realizing medicine optimized to individual patients, thereby contributing to the advancement of healthcare.